Medication Treatment for Opioid Use Disorder in Expectant Mothers
A legfontosabb adatok
- Ki végzi
- T. John Winhusen, PhD
- Hol
- Albuquerque, Boston, Charleston, Cincinnati, Huntington, Jacksonville, Nashville, Pittsburgh, Portland, Salt Lake City és Seattle (Egyesült Államok)Mind a 12 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 140 fő vett részt
- Kezdés
- 2020. júl. 21.
- Befejezés
- 2025. jan. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Buprenorphine Injection
- Buprenorphine Sublingual Product
- A regiszteradat frissítve
- 2026. június 4.
Ki vehet részt
- Életkor
- 18 év – 41 év
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Potential participants must:
- be 18-41 years of age
- be pregnant with an estimated gestational age (EGA) of 6 - 30 weeks at randomization, has evidence of a viable intrauterine pregnancy if EGA < 12 weeks and is not planning to terminate the pregnancy
- have a single fetus pregnancy (can be based on self-report if an objective assessment is unavailable)
- meet Diagnostic and Statistical Manual (DSM)-5 criteria for moderate/severe OUD and be a good candidate for BUP maintenance and/or be currently prescribed BUP for the treatment of OUD
- be willing to be randomized to BUP-XR or BUP-SL and to comply with study procedures, including weekly Medication Check Visits
- be planning to deliver at one of the hospitals for which the BORN survey was completed and that: a) has a written protocol for the management of neonatal abstinence syndrome (NAS) / neonatal withdrawal syndrome (NOWS), b) offers rooming-in while infants are being observed for NAS/NOWS; and c) does not send infants home on opioids for the treatment of NAS/NOWS
- be enrolled in outpatient addiction treatment at a participating site (e.g., have completed intake)
- be able to understand the study, and having understood, provide written informed consent in English
Ki nem vehet részt
- be currently receiving methadone or naltrexone for the treatment of OUD
- have a psychiatric condition that, in the judgment of the site medical clinician (MC), would make study participation unsafe or which would make treatment compliance difficult. Examples include:; Suicidal or homicidal ideation requiring immediate attention; Severe, inadequately-treated mental health disorder (e.g., active psychosis, uncontrolled bipolar disorder)
- be enrolled in or planning to enroll in: a) a trial testing medication for managing OUD during pregnancy; b) research testing an intervention for substance use disorder or NOWS in their infant unless they are willing to provide a release for the research records
- have a medical condition that, in the judgment of the study MC, would make study participation unsafe or which would make treatment compliance difficult. Medical conditions that may compromise participant safety or study conduct include, but are not limited to, allergy/sensitivity to study medications and the following based on clinical labs:; aspartate aminotransferase (AST) / alanine aminotransferase (ALT) greater than 5X upper limit of normal; serum creatinine greater than 1.5X upper limit of normal; total bilirubin greater than 1.5X upper limit of normal
- Potential participants must not:
- have a physiological dependence on alcohol or sedatives requiring medical detoxification
- be currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that, in the judgement of the site investigator, could prevent participation in the study or in any study activities
- be enrolled in or planning to enroll in treatment beyond the level 3.3 (Clinically Managed Population-Specific High-Intensity Residential Services) of the American Society of Addiction Medicine criteria; for level 3.3, the participant must have the ability to leave the facility unaccompanied by staff as needed
Helyszínek itt: Egyesült Államok
- University of New Mexico Milagro ClinicAlbuquerque, Egyesült Államok
- Boston Medical CenterBoston, Egyesült Államok
- Massachusetts General Hospital HOPE ClinicBoston, Egyesült Államok
- Medical University of South CarolinaCharleston, Egyesült Államok
- University of Cincinnati Health Perinatal Addictions ProgramCincinnati, Egyesült Államok
- Marshall Health MARC ProgramHuntington, Egyesült Államok
- Gateway Community ServicesJacksonville, Egyesült Államok
- Vanderbilt University Medical CenterNashville, Egyesült Államok
- Pregnancy Recovery Center at Magee-Womens Hospital of UPMCPittsburgh, Egyesült Államok
- CODA, Inc.Portland, Egyesült Államok
- University of Utah SUPeRAD ClinicSalt Lake City, Egyesült Államok
- Addiction Recovery Services (ARS), Swedish Medical CenterSeattle, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes. The primary hypothesis is that the BUP-XR group will not have greater illicit opioid use than the BUP-SL group during pregnancy (non-inferiority).
A vizsgálat 2 csoportja
- BUP-XRA vizsgált kezelés
Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly. The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).
Kezelés: Buprenorphine Injection
- BUP-SLMár használt kezelés, összehasonlításként
Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase. The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).
Kezelés: Buprenorphine Sublingual Product
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations
- Publikációk
- Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial.JAMA internal medicine, 2026
- Cigarette use and smoking cessation goals among pregnant women with opioid use disorder.Journal of substance use and addiction treatment, 2025
- Overdose risk profiles in pregnancy: Latent class analysis of pregnant individuals with opioid use disorder.Journal of substance use and addiction treatment, 2025
- Protocol Commentary for the SUCCESS (Successful Recruitment and Retention in a Randomized Controlled Trial of Pregnant Participants with Opioid Use Disorder) Study.Substance use & addiction journal, 2025
- Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder.Journal of addiction medicine, 2025
- Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study.Journal of substance use and addiction treatment, 2023
- A regiszteradat frissítve
- 2026. június 4.